FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15
Metrics: PDF 4448 views | HTML 3180 views | ?
Ningning Li1,2,*, Federica Lorenzi1,*, Eliana Kalakouti1,3,*, Makhliyo Normatova1, Roya Babaei-Jadidi1, Ian Tomlinson4, Abdolrahman S. Nateri1
1Cancer Genetics & Stem Cell Group, Cancer Biology Unit, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK
2Department of Neurodegenerative Disease, Institute of Neurology, University College London, London WC1N 3BG, UK
3Hillingdon Hospital, Uxbridge UB8 3NN, UK
4Molecular and Population Genetics Laboratory, the Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
*These authors have contributed equally to this work
Abdolrahman S. Nateri, e-mail: firstname.lastname@example.org
Keywords: FBXW7, phopsho-P53(Ser15), colorectal cancer, drug resistance, CK1α
Received: December 24, 2014 Accepted: February 05, 2015 Published: March 16, 2015
FBXW7 mutations occur in a variety of human cancers including colorectal cancer (CRC). Elucidating its mechanism of action has become crucial for cancer therapy; however, it is also complicated by the fact that FBXW7 can influence many pathways due to its role as an E3-ubiquitin ligase in proteasome degradation. FBXW7 and TP53 are tumour suppressors intensively implicated in colorectal carcinogenesis. Deletion mutations in these two genes in animal models mark the progression from adenoma to carcinoma. Although still largely unknown, the last defense mechanism against CRC at the molecular level could be through a synergistic effect of the two genes. The underlying mechanism requires further investigation. In our laboratory, we have used a phospho-kinase profiler array to illustrate a potential molecular link between FBXW7 and p53 in CRC cells. In vitro and in vivo assessments demonstrated aberrant induction of phosphorylated p53 at Serine 15 [phospho-p53(Ser15)] in human FBXW7-deficient CRC cells as compared to their FBXW7-wild-type counterparts. FBXW7 loss in HCT116 cells promoted resistance to oxaliplatin. Immunoblotting data further confirmed that reduction of phospho-p53(Ser15) may contribute to the decreased efficacy of therapy in FBXW7-mutated CRC cells. The findings may suggest the applicability of phospho-p53(Ser15) as an indicative marker of FBXW7-mutations. Phospho-p53(Ser15) regulation by FBXW7 E3-ligase activity could provide important clues for understanding FBXW7 behavior in tumour progression and grounds for its clinical applicability thereafter.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.